HIV and Hepatitis.com Coverage of the
42nd EASL Conference
April 11 - 15, 2007, Barcelona, Spain
THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER


Hepatitis B Articles

  FDA-approved Drugs

  Experimental Drugs


FDA-approved Drugs

Factors Associated with Development of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

Pegasys Suppresses HBV DNA More Than Lamivudine Over 3 Years

Liver Inflammation and Fibrosis Can Occur in Hepatitis B Patients with Normal ALT

Selected Telbivudine (Tyzeka) Studies Presented at the 42nd Annual EASL Meeting

Four-year Data on Entecavir Resistance in Nucleoside-naïve Patients with Chronic Hepatitis B

Telbivudine Provides Superior HBV Suppression Compared with Adefovir through 76 Weeks

Re-treatment with Entecavir Results in Undetectable HBV by Week 48

Entecavir Reduces HBV DNA More than Adefovir in Chronic Hepatitis B Patients at 48 Weeks

Role of HIV Coinfection in Mortality Related to Hepatitis B or C

Sustained HBeAg Response Occurs with Both Telbivudine and Lamivudine




 Experimental Drugs

Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis

HAART Regimens Containing Tenofovir Plus Lamivudine or Emtricitabine Work Best for HIV-HBV Coinfected Patients

Peginterferon Alfa-2a (Pegasys) plus Adefovir Is Safe and Results in Greater Reduction in ALT and HBV DNA Suppression than Pegasys Alone

Pegylated Interferon plus Ribavirin in Patients with HBV-HCV Dual Infection

Peginterferon Alfa-2b (PegIntron) plus Adefovir Strongly Reduces HBV cccDNA and Produces Clinical Benefit

Lamivudine/Adefovir Significantly Reduces the Development and Progression of Esophageal Varices in HBeAg-negative Patients with Cirrhosis

 













 

 

 

 

















HOME